Drug Landscape ›
DIPYRONE ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 3,252
Most-reported reactions
Pain — 395 reports (12.15%) Vomiting — 389 reports (11.96%) Nausea — 384 reports (11.81%) Pyrexia — 324 reports (9.96%) Off Label Use — 312 reports (9.59%) Dyspnoea — 302 reports (9.29%) Headache — 299 reports (9.19%) Drug Ineffective — 293 reports (9.01%) Abdominal Pain — 280 reports (8.61%) Anaemia — 274 reports (8.43%)
Source database →
DIPYRONE in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is DIPYRONE approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for DIPYRONE in United States?
Marketing authorisation holder not available in our data.